Literature DB >> 9710449

HIV-1 envelope gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes.

H Ueda1, O M Howard, M C Grimm, S B Su, W Gong, G Evans, F W Ruscetti, J J Oppenheim, J M Wang.   

Abstract

HIV-1 uses CD4 and chemokine receptors as cofactors for cellular entry. The viral envelope transmembrane protein gp41 is thought to participate in viral fusion with CD4(+) cells. We investigated whether gp41 interacts with chemokine receptors on human monocytes by testing its effect on the capacity of cells to respond to chemokine stimulation. Monocytes preincubated with gp41 of the MN strain showed markedly reduced binding, calcium mobilization, and chemotaxis in response to a variety of chemokines as well as to the bacterial peptide fMLP. This generalized inhibition of monocyte activation by chemoattractants required the presence of CD4, since the effect of gp41 was only observed in CD4(+) monocytes and in HEK293 cells cotransfected with chemokine receptors and an intact CD4, but not a CD4 lacking its cytoplasmic domain. Confocal microscopy showed that gp41 caused internalization of CXCR4 in HEK293 cells provided they were also cotransfected with intact CD4. In addition, pretreatment of monocytes with protein kinase C inhibitors partially reversed the inhibitory effect of gp41. Thus, gp41, which had not previously been implicated as interacting with HIV-1 fusion cofactors, downregulates chemoattractant receptors on monocytes by a CD4-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710449      PMCID: PMC508943          DOI: 10.1172/JCI3273

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

Review 1.  Neutralization of HIV-1: a paradox of humoral proportions.

Authors:  P L Nara; R R Garrity; J Goudsmit
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

2.  Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

Authors:  E O Freed; D J Myers; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes.

Authors:  S M Wahl; J B Allen; S Gartner; J M Orenstein; M Popovic; D E Chenoweth; L O Arthur; W L Farrar; L M Wahl
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation.

Authors:  U D'Oro; M S Vacchio; A M Weissman; J D Ashwell
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

6.  Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1.

Authors:  J E Merrill; Y Koyanagi; J Zack; L Thomas; F Martin; I S Chen
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis.

Authors:  P D Smith; K Ohura; H Masur; H C Lane; A S Fauci; S M Wahl
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides.

Authors:  N M Qureshi; D H Coy; R F Garry; L A Henderson
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

View more
  8 in total

Review 1.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

2.  HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection.

Authors:  Chang Zhou; Lu Lu; Suiyi Tan; Shibo Jiang; Ying-Hua Chen
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

3.  Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility.

Authors:  Tien Hsu; Yair Adereth; Nurgun Kose; Vincent Dammai
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

4.  Recombinant interleukin-16 selectively modulates surface receptor expression and cytokine release in macrophages and dendritic cells.

Authors:  E Hermann; E Darcissac; T Idziorek; A Capron; G M Bahr
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

Review 5.  HIV-1 gp41 and type I interferon: sequence homology and biological as well as clinical implications.

Authors:  Y H Chen; Y Xiao; M P Dierich
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

6.  Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor.

Authors:  John S Mills
Journal:  Biochim Biophys Acta       Date:  2006-06-06

7.  Differential activation of polymorphisms of the formyl peptide receptor by formyl peptides.

Authors:  John S Mills
Journal:  Biochim Biophys Acta       Date:  2007-06-14

8.  Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.

Authors:  Ali Işbilir; Jan Möller; Marta Arimont; Vladimir Bobkov; Cristina Perpiñá-Viciano; Carsten Hoffmann; Asuka Inoue; Raimond Heukers; Chris de Graaf; Martine J Smit; Paolo Annibale; Martin J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-04       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.